August 31, 2020
Aimmune Therapeutics Inc, a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, has announced that it has entered into a definitive agreement with Sociétés des Produits Nestlé, S.A. to acquire Aimmune for US$34.50 per share in an all-cash transaction, implying a fully-diluted equity value of US$2.6 billion. Sociétés des Produits Nestlé, S.A. is a part of Nestlé Health Science and a wholly owned subsidiary of Nestlé S.A.
Latham & Watkins LLP represents Aimmune Therapeutics Inc. in the transaction with a corporate deal team led by Bay Area partners Patrick Pohlen, Luke Bergstrom, and Miles Jennings, with Orange County associates Brett Urig, Christopher Martinez, Stephanie Isaia, Oliver Cohen, and Gabrielle Masse, Bay Area associate Rachelle Polsky, and Chicago associate Ryan Hudson. Advice was also provided on benefits and employment matters by Bay Area partners James Metz and Erin Murphy, with Bay Area associate Erik Ward; on antitrust matters by Washington, D.C. partner Mandy Reeves, Washington, D.C. counsel Peter Todaro, Brussels counsel Tomas Nilsson, and Hamburg counsel Jana Dammann; on intellectual property matters by Bay Area partner Judith Hasko, with Bay Area associate Katie Mladinich; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang and Heather Deixler, with Washington, D.C. associate Eitan Bernstein; and on tax matters by Bay Area partner Grace Lee, with Los Angeles associate Brian Rogers.